Valuation : Biogen Inc.

Market Cap 32.9B 28.31B 26.56B 24.3B 45.36B 3,110B 45.72B 314B 122B 1,589B 124B 121B 5,119B P/E 2026 *
39.6x
P/E 2027 * 19.5x
Enterprise Value 37.84B 32.56B 30.55B 27.95B 52.17B 3,577B 52.58B 361B 141B 1,828B 142B 139B 5,887B EV / Sales 2026 *
3.62x
EV / Sales 2027 * 3.31x
Free-Float
85.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.67%
1 week+1.84%
Current month+1.94%
1 month+8.11%
3 months+19.44%
6 months+19.49%
Current year+27.60%
1 week 184.24
Extreme 184.24
193.3
1 month 174.28
Extreme 174.28
193.3
Current year 137.85
Extreme 137.85
193.3
1 year 116.45
Extreme 116.45
193.3
3 years 98.96
Extreme 98.96
254.4
5 years 98.96
Extreme 98.96
305
10 years 98.96
Extreme 98.96
348.1
Manager TitleAgeSince
Chief Executive Officer 66 14/11/2022
Director of Finance/CFO 60 01/03/2025
Chief Tech/Sci/R&D Officer - 28/10/2024
Director TitleAgeSince
Director/Board Member 69 23/03/2010
Director/Board Member 77 01/01/2010
Director/Board Member 72 19/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.67%+1.84% - - 32.9B
-1.00%+4.43%+49.60%+2.50% 85.08B
-1.29%+4.27%+519.00%+36.13% 60.21B
+0.95%+1.77%-15.77%-34.78% 59.71B
-1.60%-7.63%-3.65%+31.05% 51.1B
+0.09%-0.14%+11.61%+165.71% 48.73B
+0.83%+1.36%+58.53%-15.69% 32.9B
-0.64%+0.20%+47.19%+102.28% 26.11B
+0.79%-6.56%-2.56%+192.31% 22.6B
+1.10%-0.90%+67.27%+118.01% 16.42B
Average -0.11%-1.40%+81.25%+66.39% 44.76B
Weighted average by Cap. -0.40%-0.78%+97.08%+45.70%

Financials

2026 *2027 *
Net sales 10.45B 8.99B 8.44B 7.72B 14.41B 988B 14.52B 99.83B 38.88B 505B 39.25B 38.39B 1,626B 10.67B 9.18B 8.61B 7.88B 14.71B 1,008B 14.82B 102B 39.68B 515B 40.05B 39.18B 1,660B
Net income 953M 820M 770M 704M 1.31B 90.09B 1.32B 9.1B 3.55B 46.04B 3.58B 3.5B 148B 1.9B 1.63B 1.53B 1.4B 2.62B 180B 2.64B 18.14B 7.06B 91.75B 7.13B 6.98B 295B
Net Debt 4.94B 4.25B 3.99B 3.65B 6.81B 467B 6.86B 47.15B 18.36B 238B 18.54B 18.13B 768B 2.42B 2.08B 1.95B 1.79B 3.34B 229B 3.36B 23.11B 9B 117B 9.09B 8.89B 377B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change
02/09/26 191.72 +3.14%
03/09/26 €193.30 +0.82%
02/09/26 €191.72 +3.14%
01/09/26 €185.88 -1.17%
31/08/26 €188.08 +0.09%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
222.67USD
Average target price
236.87USD
Spread / Average Target
+6.37%

Quarterly revenue - Rate of surprise